A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MORPHEUS- CRC)

Protocol: 
AAAR8538
Phase: 
I/II

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MORPHEUS- CRC)

The purpose of this study is to compare the effects, good or bad, of the
cancer immunotherapy combination treatments (CIT) combinations versus standard
treatment on you and your colorectal cancer to find out which is better.

Are you Eligible? (Inclusion Criteria)

1) Are you 18 years of age or older?

2) Do you have Metastatic Colorectal Cancer (mCRC)?

3) Did you have disease progression during or following two separate lines
of treatment for mCRC?

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States